CNS/Ocular delivery
Designed MSNs can enhance bioavailability of therapeutics by overcoming biological barriers and increasing the penetration in diseased regions.
Multidrug co-delivery
Co-loading and co-delivering drugs at an optimal ratio reveal synergistic effects in the treatment of intractable cancers.
Selective Surface Functionalization
Tailor-made MSNs with specific interior or exterior surface modifications are available for various applications.
Injectable/Oral nanoformulation
Products can be crafted into liquid as well as solid dosage forms, such as suspensions and tablets for different administration routes.
Site-Specific Targeting
MSNs proceed by targeting strategies allow maximum therapeutic concentration to the diseased region while reducing side effects.
Drug Delivery
Versatile MSNs can carry payloads, including hydrophilic and hydrophobic chemicals as well as biologics, precisely and safely to the target sites.
Mesoporous Silica Nanoparticles as a Drug-Delivery Platform for Overcoming the Hurdles of Drug Delivery
Mesoporous Silica Nanoparticle (MSN) as drug delivery systems have been deemed to have wide therapeutic applications due to their unique physical/chemical properties, such as chemical/thermal stability, high loading capacity, adjustable surface properties and excellent biocompatibility.

NTT Biopharma technology offers customizable MSNs with modulated nanoparticle size, surface charge, and constitution, etc., to overcome biological barriers such as the blood-brain barrier, the blood-ocular barrier, and small intestines. NTT Biopharma develops MSN with unique properties that can increase the penetration of biological barriers and improve bioavailability. Moreover, poor water solubility of some drugs can be managed with MSN nanoformulation to create good dispersity and higher solubility in aqueous solution (a million times greater!), that can be used via multiple administration routes including parenteral, oral, ocular, etc.
Proprietary Mesoporous Silica Nanoparticles Platforms for Cancer Therapy
Mesoporous silica nanoparticles can be designed to deliver various kinds of bioactive ingredients including small molecules, chemotherapy drugs, peptides, proteins, DNA, and RNA to target sites, moreover, MSNs offer the capability to co-deliver multiple drugs in a nanoformulation for combination therapy. For treating cancer more efficiently and safely, NTT Biopharma has been developing MSNs that target tumors, cross the blood-brain barrier, and reduce adverse effects.
NTT Biopharma has also developed a unique hollow silica nanosphere (HSN) for immuno-oncology therapy, HSN can be both self-adjuvant and antigen carrier simultaneously to enhance immune response for improving the effectiveness of cancer immunotherapy or cancer vaccines. HSN can encapsulate antigens in the hollow space of HSN and keep the antigens from leaking out and being degraded by proteases in the circulation. The lymph node and tumor targeting capability of HSN effectively and robustly induces immune responses and modulates the tumor microenvironment that lead to increasing antigen specific T cells and TIL around the tumor region and killing the cancer cells.
The Unique Value of Mesoporous Silica Nanoparticle
NTT Biopharma's MSN is a novel drug-delivery platform of silica nanoparticles, which possesses several key properties as listed below:
  • Safety:
    - Mesoporous silica nanoparticles are biocompatible and biodegradable. They are excreted through feces or urine in a partially degraded form or dissolved silica species (silicic acid).
    - Silica is considered as a GRAS substance (Generally Recognized as Safe) by FDA.
  • Tailor-made MSNs and diverse payloads:
    - Tailor-made MSNs with specific particle size and interior or exterior surface modifications are available for versatile applications.
    - MSNs can carry various bioactive ingredients including hydrophilic and hydrophobic chemicals as well as biologics, and deliver them precisely and safely to target sites.
  • Stable and diverse dosage forms:
    - Controllable surface modifications make MSNs loaded with bioactive ingredients highly dispersible and suspend easily in aqueous solution and are storable as liquid or solid forms.
    - Administration routes of nanoformulations can be parenteral (such as intravenous, oral, etc.) as well as local (such as intravitreal, eye drops, etc.).